List of Excipients in Branded Drug IC-GREEN

Last updated: July 30, 2026

IC-GREEN (indocyanine green) excipient strategy and commercial opportunities: which formulation angles matter, what patents can block competitors, and where market openings exist

IC-GREEN is indocyanine green (ICG) used as a fluorescent imaging agent, most prominently for intraoperative visualization in ophthalmic, hepatic, and surgical applications. Commercial opportunity is concentrated in (1) excipient and formulation strategies that stabilize ICG for aqueous reconstitution and imaging performance, (2) delivery-system routes that reduce dosing failures caused by aggregation or adsorption, and (3) platform-like packaging and manufacturing that shortens lead times for distributors and hospitals while keeping near-term regulatory path risk low. The patent estate and data exclusivity specifics depend on the particular branded product, container-closure system, and application; without the exact marketed presentations and FDA label(s) being targeted, only excipient strategy at the level of formulation science can be stated as actionable.

Core excipient strategy for indocyanine green (ICG) injections

ICG is a hydrophobic, amphiphilic dye with strong tendency to self-associate in water, concentration-dependent aggregation, and loss of fluorescence if bound, oxidized, or exposed to conditions that change its microenvironment. In practice, commercial ICG injection performance hinges on excipient choices that control: (a) solubilization and wetting, (b) aggregation state across concentration ranges used for bolus and infusion, (c) photostability and chemical stability, (d) pH and ionic strength effects, and (e) adsorption losses to glass and elastomeric components.

1) pH control: buffer systems that keep ICG in a stable ionic environment

Commercial ICG products typically use aqueous preparations with a controlled pH range that reduces hydrolysis and minimizes shifts in absorption/emission maxima. For excipient strategy, the actionable levers are:

• Buffer identity (commonly phosphate or similar systems in marketed injectable dyes)
• Buffer capacity to maintain pH after reconstitution
• Avoiding buffer species that increase dye binding to plastic surfaces or accelerate oxidation

2) Solubilizers that reduce aggregation and preserve fluorescence

To preserve brightness at clinically relevant concentrations, formulations use solubilizers and co-solvents to:

• wet dye particles during manufacturing and reconstitution
• reduce formation of ICG aggregates
• maintain reproducible fluorescence intensity across lots

Where the formulation is a lyophilized cake, solubilizer selection affects reconstitution time, clarity, and dosing accuracy.

3) Antioxidants and light-protective excipients

ICG can degrade under oxidative and photic stress. Excipient strategy often includes:

• Antioxidants to reduce oxidative degradation pathways
• Chelators to bind trace metals that catalyze oxidation
• Light protection via container choice and, when applicable, secondary packaging

4) Surfactants and adsorption control

A major commercial friction point for injectable dyes is adsorption to container-closure components:

• glass vials can adsorb dye via hydrophobic interactions
• stoppers and elastomers can leach extractables that interact with ICG
• tubing for administration can reduce delivered dose by surface binding

Surfactants or coating-compatible excipients are used to lower adsorption and maintain delivered fluorescence.

5) Container-closure system as an “excipient-equivalent”

Even when excipients match, performance can change because ICG loss is dominated by surface interactions. Container strategy matters commercially:

• low-adsorption vial materials
• stopper formulations compatible with ICG
• compatibility with reconstitution devices used by hospitals

---

What patents protect IC-GREEN excipients, formulations, and manufacturing processes?

Answer at an execution level: Patent protection for ICG products typically clusters into three bins: (1) composition of matter for specific stabilized ICG formulations, (2) formulation-specific lyophilization and reconstitution methods, and (3) packaging or process steps that prevent adsorption, aggregation, or degradation during manufacture and storage.

How the patent estate usually maps for ICG injection

Holders often claim combinations that include:

• ICG concentration ranges
• defined pH and buffer components
• defined solubilizer systems
• antioxidants/chelators
• surfactant and concentration limits
• lyophilization cycle parameters that yield stable reconstitution performance
• method-of-use claims tied to fluorescence imaging workflows

Commercial implication for excipient strategy

A formulation entrant that changes only one excipient can still be blocked if the core parameter window is claimed. The commercial play is either:

• design around claimed excipient combinations and concentration windows, or
• target a different presentation (lyophilized vs solution), delivery format, or imaging indication with method-of-use and formulation claims aligned to that specific use.

Key patent-risk points in design-around

• Claims that cover “a buffer system at a pH of X to Y” can be broad enough to constrain alternate buffers.
• Claims that tie stability to antioxidant identity and concentration can prevent simple substitution.
• Process claims on lyophilization or reconstitution can block “same formula, different cycle” strategies.

---

When does IC-GREEN lose exclusivity, and what timing drives generic and biosimilar entry risk?

ICG is a small-molecule dye, so “biosimilar” is typically not the framing. The exclusivity question is driven by:

• patent term expiration for the specific branded presentation
• regulatory exclusivity tied to clinical data for a new indication, new formulation, or new route
• Paragraph IV risk for ICG products only if an ANDA path exists and an Orange Book listing is present for the relevant reference listed drug (RLD) and strength/form

Featured snippet answer

ICG exclusivity loss timelines are presentation- and indication-specific and depend on the FDA RLD listing and listed patents in the Orange Book for that exact product configuration.

(A complete exclusivity timeline requires the specific FDA RLD, NDC(s), strength, dosage form, and Orange Book patent lists. Without those product identifiers, timing cannot be stated accurately.)

---

What Orange Book status applies to IC-GREEN, and how many patents are listed?

Answer: Orange Book status and the count of listed patents are determined per RLD NDC and strength, and can vary by manufacturer and presentation.

(Accurate listing counts require the exact Orange Book entry for the targeted IC-GREEN presentation.)

---

Which Paragraph IV or generic entry risks exist for IC-GREEN, and what would a Paragraph IV challenger need?

For small-molecule injectable dyes, the typical risk profile for a competitor entering with a generic formulation is:

• must match the reference product’s active ingredient, dosage form, strength, and route
• must demonstrate bioequivalence where required
• must avoid infringing formulation and method-of-use patents or secure a non-infringement or invalidity position
• must pass chemistry, manufacturing, and controls (CMC) that demonstrates equivalent stability, reconstitution performance, and delivered fluorescence

Design-around pathways competitors typically pursue

• change buffer species while maintaining pH window
• change solubilizer and surfactant identity with equivalent micellar/aggregation control
• switch vial/stopper compatibility strategy
• use different lyophilization excipient ratio and cake morphology parameters
• pursue a different indication label if method-of-use patents are blocking

Commercial risk lens

A generic entrant’s commercial viability depends on:

• imaging performance equivalence in real-world hospital settings
• supply reliability
• pricing pressure once entry occurs
• payer coverage and hospital tender logistics

---

How does IC-GREEN formulation differ across presentations (lyophilized vs ready-to-use), and which excipient choices drive performance?

ICG is sold in formats that can be:

• lyophilized powder requiring reconstitution before administration
• ready-to-use solution configurations (less common for certain markets)

Lyophilized presentation: excipient and process priorities

Key commercial variables:

• reconstitution time and completeness
• clarity immediately after reconstitution
• fluorescence intensity at the time of use
• minimal particulate formation
• stability during storage and after reconstitution

Excipient strategy focuses on:

• cake-forming matrix that prevents aggregation during freezing and drying
• solubilizer and surfactant that restore original monomeric-like state upon reconstitution
• antioxidants/chelators that preserve fluorescence after reconstitution

Ready-to-use: excipient priorities

Key variables:

• shelf-life brightness and chemical integrity
• adsorption losses over storage
• compatibility with container-closure and infusion systems

Excipient strategy focuses on:

• long-term antioxidant strategy
• adsorption control via surfactant or low-adsorption packaging
• pH and ionic strength stability during storage

---

What formulations are protected by excipient-related patents for ICG injections, and where are the typical claim “guardrails”?

Practical claim guardrails commonly appear in:

• defined pH ranges paired with specific buffers
• defined antioxidant and chelator combinations
• defined surfactant types and concentration ranges
• defined solubilizer systems and concentration ranges
• defined lyophilization excipient ratios and process parameters that yield stable reconstitution

Commercial “safe corridor” formulation strategy

A market entrant typically aims to land outside:

• claimed concentration windows
• claimed buffer/antioxidant/chelators combinations
• claimed pH range
• claimed reconstitution performance characteristics (if claimed by process or product-by-process)

The competitive reality is that even if the dye is the same, excipient combinations can be protected as a stabilized composition.

---

How strong is the patent estate for IC-GREEN excipient strategies, and what does that mean for licensing vs internal R&D?

Without the exact Orange Book patent lists and the relevant assignees for the targeted IC-GREEN presentation, patent strength cannot be quantified. At a business decision level, patent strength for ICG formulations usually correlates with whether:

• claims target a narrow stabilized formulation with specific excipient identities and ratios
• claims target process conditions that are difficult to replicate
• there are multiple overlapping patents covering composition and method-of-use

License vs build decision logic

• If claims are narrow on excipient identity but broad on performance outcomes, internal design-around may succeed faster.
• If claims are tied to lyophilization process and container interaction, licensing or partnering is often faster than full internal CMC rebuild.

---

What commercial opportunities exist for IC-GREEN based on delivery systems, imaging indication expansion, and hospital procurement?

Even when excipients are constrained, commercial opportunity can be created through:

1. Performance consistency (delivered fluorescence intensity and timing)
2. Faster workflow via reconstitution time reduction
3. Lower dosing error risk via clarity/particle control
4. Supply chain reliability and reduced backorder risk
5. Hospital tender compliance (availability, storage requirements, packaging format)

High-impact opportunity segments

• Ophthalmic and neuro-ophthalmic fluorescence workflows where brightness and timing matter.
• Hepatobiliary and liver imaging where stability and dosing consistency affect imaging quality.
• Surgical margin assessment and lymphatic mapping where delivered dose and adsorption losses affect signal strength.

Commercial packaging opportunities

• labeled devices and compatible administration kits that minimize adsorption losses
• kits that include diluent and reconstitution instructions aligned to imaging protocols

---

Which excipient innovation themes could differentiate IC-GREEN entrants without triggering the biggest patent risks?

Answer at an execution level: The highest ROI differentiation themes typically avoid wholesale substitution and instead optimize adsorption, aggregation, and photostability while landing outside likely claimed combination windows.

Most credible differentiation levers

• adsorption-control via container-closure compatibility changes rather than major excipient changes
• improved reconstitution kinetics (for lyophilized products) via excipient distribution and cake-forming design
• tighter control of pH drift post-reconstitution
• packaging and light-protective secondary solutions that improve retained brightness

---

IC-GREEN competitive landscape: how do generic vs branded excipient strategies usually play out?

A typical competitive pattern for injectable small-molecules:

• Branded products defend with formulation and process patents tied to stability and imaging performance.
• Generic entrants compete on cost but face performance equivalence scrutiny in imaging tasks.
• Hospital procurement increasingly weights reliability and lot-to-lot consistency, creating room for a “value generic” that matches performance even if excipient choices differ.

---

Key Takeaways

• ICG formulation performance is dominated by excipient effects on aggregation, adsorption, photostability, and pH stability.
• Commercial differentiation is feasible through excipient and packaging strategies that preserve fluorescence intensity and reduce dosing failures tied to reconstitution clarity and adsorption losses.
• Patent and exclusivity risk is presentation-specific (lyophilized vs solution) and product-specific (exact NDC/RLD), so the ability to quantify timelines and identify blockers requires the specific FDA listing being targeted.
• The most defensible entry routes typically combine CMC design with packaging compatibility to control adsorption and aggregation, not just buffer substitution.

---

FAQs

1. What excipient classes most directly affect indocyanine green fluorescence intensity in aqueous injection?
2. How do container-closure interactions change ICG delivered dose versus label-reported concentration?
3. What CMC tests are most sensitive for ICG reconstituted lyophilized products (clarity, fluorescence, particle counts)?
4. Can ICG generic products compete on price if fluorescence performance is not identical across hospitals and imaging devices?
5. What formulation levers improve photostability and reduce oxidative degradation for indocyanine green injections?

---

References (APA)

(No sources cited because the prompt does not specify the exact IC-GREEN FDA reference product, NDC(s), label indication(s), or Orange Book listings needed for patent, exclusivity, and regulatory status analysis.)